ストックスクリーナーアプリを入手
65.37
1.48%
-0.98
アフターアワーズ：
64.03
-1.34
-2.05%
前日終値:
$66.35
開ける：
$66.65
24時間の取引高:
1.26M
Relative Volume:
0.67
時価総額：
$8.05B
収益：
$88.04M
当期純損益:
$-784.96M
株価収益率:
-10.01
EPS:
-6.5335
ネットキャッシュフロー:
$-534.82M
1週間 パフォーマンス:
-0.61%
1か月 パフォーマンス:
+8.84%
6か月 パフォーマンス:
+4.09%
1年 パフォーマンス:
+69.53%
1日の値動き範囲:
$64.74
$67.25
1週間の範囲:
$63.95
$67.90
52週間の値動き範囲:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
65.37 | 8.17B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Wells Fargo | Overweight |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Blum Robert I, president & CEO of Cytokinetics, sells $490k in stock - Investing.com
Cytokinetics EVP Callos sells $491k in stock - Investing.com
Cytokinetics Incorporated : Read Our 2025 Report - marketscreener.com
Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference - Yahoo Finance
Cytokinetics Inc stock (US2328281044): Does cardiac muscle therapy execution now define its biotech - AD HOC NEWS
Fed Watch: Is Cytokinetics Incorporated undervalued by DCF analysisSwing Trade & Verified Short-Term Plans - baoquankhu1.vn
CYTK Analyst Rating: Wells Fargo Initiates Overweight April 2026 - Meyka
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Q1 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Earnings Transcripts - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock News, Headlines & Updates - GuruFocus
Market Review: What are the future prospects of Cytokinetics IncorporatedAnalyst Downgrade & Real-Time Price Movement Reports - baoquankhu1.vn
Wells Fargo initiates coverage of Cytokinetics (CYTK) with overweight recommendation - MSN
CYTK Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Momentum Shift: Is Cytokinetics Incorporated stock heavily shortedWeekly Profit Analysis & Scalable Portfolio Growth Methods - baoquankhu1.vn
Risk Recap: Will Cytokinetics Incorporated stock go up in YEAR2026 Pullback Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Cytokinetics Inc (HAM:KK3A) Valuation: Possible Value Trap, Think Twice - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Cytokinetics Inc (HAM:KK3A) Stock Today? - GuruFocus
Cytokinetics Inc Stock Operating Data - GuruFocus
Cytokinetics (CYTK) EVP Malik sells $292,985 in stock By Investing.com - Investing.com India
Cytokinetics (CYTK) EVP Malik sells $292,985 in stock - Investing.com
Insider Sell: Fady Malik Sells 4,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $292,985, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (CYTK) EVP nets 4,500-share sale after option exercises - Stock Titan
CYTK Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CYTK (NASDAQ: CYTK) insider sale filing lists 22,000-share option exercise - Stock Titan
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Australia
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Barclays Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - MarketBeat
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Aberdeen Group plc Sells 444,771 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock forecasts - uk.finance.yahoo.com
CYTK PE Ratio & Valuation, Is CYTK Overvalued - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $95 - Moomoo
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cytokinetics (CYTK): CEO Blum sells $499k in shares - Investing.com UK
Cytokinetics (CYTK): CEO Blum sells $499k in shares By Investing.com - Investing.com Canada
Insider sale: Cytek (NASDAQ: CYTK) files to sell 45,000 RSUs - Stock Titan
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares, retains large stake - Stock Titan
CYTK Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Callos, Cytokinetics EVP, sells $236k in shares By Investing.com - Investing.com South Africa
Callos, Cytokinetics EVP, sells $236k in shares - Investing.com
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):